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Introduction — why PET/MR?
In the last decade, PET/CT (Figure 1) imaging systems have 
become an essential tool for staging and restaging various types of 
malignant tutors and have been shown to have a significant impact 
on patient management [1, 2]. PET/CT also shows exciting po-
tential in predicting the response to treatment for several types of 
cancer, including metastatic breast cancer [3], lung cancer [4], 
and lymphomas [5].
The clinical and commercial success of combined PET and 
CT imaging modality was primarily driven by the complementary 
character of data derived from each of the imaging modalities: 
anatomical detail of the CT and metabolic, molecular level informa-
tion delivered by PET imaging (Figure 2A). In addition, the clinical 
workflow improvement and ease of use of the combined system 
cannot be overlooked.
Integration of CT and PET addressed some of the critical 
questions in diagnosis and staging of the disease: combination 
of lesions detectability (with FDG PET) and their localization (with 
CT). It also paved the way for further integration of other imaging 
modalities. For example,  an increasing number of SPECT cam-
eras are being replaced by combined SPECT/CT systems.
With the evolution of MR imaging techniques, MR imaging 
studies can provide additional diagnostic information regarding 
soft-tissue analysis, tumour detection, tissue characterization, and 
functional imaging (Figure 2B). It is not uncommon today for onco-
logy patients to have both PET/CT and MR imaging scans providing 
complementary diagnostic data [6]. In some cases, the diagnostic 
value of MR for detection and staging of cancers can be superior 
to CT studies. This limits the value of the diagnostic CT studies that 
can be performed in combination with the PET/CT study to a simple 
anatomical localization and attenuation correction scan. 
It is therefore quite rational to anticipate that a hybrid PET-MRI 
scan could be more valuable in such cases than a PET/CT scan 
followed by a complementary MRI scan [7]. In addition, whole 
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Figure 1. GEMINI TF PET/CT system (Philips Healthcare, Cleveland, 
Ohio, USA).
Figure 2A. Anatomical detail is the main strength of CT imaging. 
Nuclear medicine imaging and PET in particular, provide metabolic 
information at the molecular level.
Figure 2B. MR imaging has a unique characteristic combining both 
anatomical detail and physiological, metabolic information. Combining 
these strengths of MRI with nuclear medicine imaging enables the 
study of multiple biomarkers during a single patient examination. 
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body MRI alone has been reported to have excellent diagnostic 
performance and has been proposed as an alternative to, or re-
placement for, PET/CT [8]. Whole body MRI, especially diffusion 
weighted sequences that showed high sensitivity, are being used 
increasingly in oncology for initial diagnosis or follow-up staging, 
as well as assessment of metastases, staging for pregnant woman 
and children, and follow-up of therapeutic response [9]. 
This promise to provide a comprehensive picture of patient 
anatomy (imaged by MR) combined with multi-parameter lesion 
characterization (imaged by PET and advanced MR imaging tech-
niques) makes an integrated PET/MR system a leading candidate 
for the molecular imaging “dream team”.
System design
In 2010, Philips Healthcare introduced the Ingenuity TF 
PET/MR, an integrated PET/MR hybrid imaging system similar to 
a PET/CT (Figure 3). The whole body PET-MRI system consists of 
a GEMINI TF PET system and an Achieva 3T X-series MRI system. 
The two scanners are separated by approximately 3 metres, with 
a sliding patient table between the two, allowing sequential imaging 
in each of the scanners with the patient staying perfectly still on 
the table. This system design was driven by the requirements of 
uncompromised performance of both modalities, full whole body 
imaging capabilities for PET and MR imaging and integrated 
clinical workflow. 
Technical challenges
There are two critical technical areas that have to be addressed 
when considering an integrated PET/MR scanner:
— possible interference between the two modalities;
— use of MR imaging for the purpose of PET attenuation cor-
rection.
Compared to PET/CT, modifications to the PET were made 
to avoid mutual system interference and deliver uncompromis-
ing performance that is equivalent to the standalone systems. 
System separation, additional shielding of the PET system, and 
placement of sensitive electronics in a separate equipment room 
were implimented to minimize possible interference. In particular, 
the PET gantry was redesigned to introduce magnetic shielding 
for the photomultipliers (PMTs), which ensured their operation in 
‘normal’ flux levels close to the Earth’s magnetic field. 
Attenuation correction for clinical imaging represents the 
biggest challenge facing those working in the field of PET/MRI. 
Philips implemented a 3-segment approach for generation of MR 
based attenuation maps (Figure 4). 
In addition to image segmentation, one needs to consider the 
attenuation of the patient table and the coils used for MR imaging. 
Neither of these is visible on the MR image and have to be inserted 
by software into the PET attenuation map. Figure 5 shows at-
tenuation maps of different coils available on the Ingenuity TF 
PET/MR system. 
Initial evaluation indicates that PET images obtained from 
the PET/MR system, reconstructed with default reconstruction 
method, portrayed good image fidelity qualitatively comparable 
to PET/CT.
System performance
The PET NEMA results obtained with PET/MR are comparable 
to typical GEMINI TF PET/CT. System energy and time of flight tim-
ing resolution were comparable to PET/CT, confirming the benefit 
of magnetic shielding to maintain the PMTs in normal flux levels. 
There is a slight decrease in peak NECR (Figure 6) and a minor 
increase in IEC background variability, which can be attributed to 
a thicker patient table used in the PET/MR system. Overall, the 
results demonstrate that both PET and MRI can function in close 
proximity without compromising PET imaging performance and 
quality. 
Figure 3. The Ingenuity TF PET/MR (Philips Healthcare, Cleveland, 
Ohio, USA) combines Philips time of flight PET technology (gantry on 
the left) with Philips Achieva 3T MR system (gantry on the right). Typi-
cally, the patient undergoes a fast MR imaging scan for the purpose of 
anatomical localization and attenuation correction, followed by a PET 
scan and then any additional MR imaging sequences. The patient 
table rotates between the scans but the patient remains in the original 
position. PET imaging is performed with MR coils in place.
Figure 4. Attenuation correction of PET images using an attenuation 
map generated from automatic segmentation of whole-body MR ima-
ges. From left to right: uncorrected PET image, MR attenuation cor-
rection sequence, segmented attenuation correction map at 511 keV, 
attenuation corrected PET image. Patient data courtesy of Prof. Ratib, 
HUG, Geneva, Switzerland.
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The Table 1 shows GEMINI TF PET/CT typical NEMA val-
ues compared to Ingenuity TF PET/MR. Time of flight timing 
resolution and energy resolution of the PET/MR system were stable 
over time and were measured to be 520 ps and 12%, respectively. 
The 3T MR system is sensitive to frequencies in the range of 
32 MHz to 128 MHz (e.g. for multinuclear). RF noise generated 
from electronics situated inside the PET gantry shows distinct 
MR artefacts [10]. While a normal PET system has EMI emis-
sions that meet all regulatory requirements, requirements for 
MRI are far more stringent. To obviate these issues, PET system 
modifications were made to move all electronics from the PET 
gantry to the equipment room, where it is easier to mitigate 
spurious noise transmissions. The PET gantry contained only 
the normal crystal/PMT geometry and the first level of signal 
processing boards. All power and signal cables penetrating the 
MR walls were filtered through specially designed RF penetra-
tion panels to prevent extraneous EMI radiation from entering 
the imaging suite through the cables. Further, PET acquisition 
electronics were enclosed in an RF-tight cabinet which provided 
shielding effectiveness of 40 dB @ 1 GHz frequencies. These 
design changes allowed the elimination of the effects of the PET 
system on MR performance and image quality.
Figure 6. Random, true, scatter, and noise-equivalent count rate curves for Ingenuity TF PET/MR system. NEC [NEC = Trues2/(Trues + Scat-
ter + Ran doms)] performance vs. activity and scatter fraction measured using the 20 cm diameter × 70 cm long phantom with 555 MBq in a 70 cm 
line source at 4.5 cm from the central axis of the cylinder.
Figure 5. Attenuation templates for the patient table and different MR coils.
Table 1. Comparison of values of GEMINI TF PET/CT and Ingenuity TF PET/MR
Specification GEMINI TF PET/CT Ingenuity TF PET/MR
Spatial res. 1 cm transverse (FWHM) 4.7 mm 4.7 ± 0.1 mm
Sensitivity 0 cm/10 cm (cps/MBq) 7000/7200 7000 ± 155/7200 ± 142
NECR Max (kcps) — 20 cm 110 90 ± 3
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Overall, the system performance demonstrates that both PET 
and MRI can function in close proximity without compromising PET 
and MR imaging specifications and image quality.
Clinical applications
The Ingenuity TF PET/MR has been designed to perform 
uncompromised PET and MR imaging for the entire spectrum of 
clinical applications. PET/MR as a new imaging modality has great 
potential to build on and extend the success of PET/CT by being 
able to provide more insight into relevant tumour biomarkers and 
better characterize cardiovascular, neurological, and other diseases.
There are two broad clinical applications for PET/MR that can 
potentially result in enormous benefit for the patient [11]:
— support the entire care cycle (diagnosis-treatment-monitoring) 
process;
— support the development of drugs by allowing the study of 
tumour growth and function, as well as the mechanisms of 
action that make a drug effective.
Screening and diagnosis
For some applications, screening programs could be intro-
duced with a lower risk of exposing the patient population to 
radiation, by avoiding CT exposure. The excellent soft tissue dis-
crimination and high resolution of MRI complement the sensitivity 
of PET imaging, making a diagnosis that is more firm, accurate, 
and reliable. Some preliminary work indicates that high-risk plaque 
characterization could be a possible application in this phase of 
the care cycle.
More accurate staging
In some types of cancer, PET/CT demonstrated some limita-
tions for accurate cancer staging. A hybrid PET/MR, based on 
better soft tissue contrast, improves the potential for accurate 
tumour staging. MR can also more clearly discriminate the uptake 
of the PET tracer in areas that are active but not related to the 
tumour, such as brain, thyroid gland, striated muscle, bone mar-
row, digestive tract, and genitourinary tract. This could therefore 
reduce the number of false positives.
Better therapy planning
PET/MR could potentially provide truly individualized therapy 
planning for patients by providing additional information to better 
characterize the tumour. Today, PET/CT provides the anatomical 
extent of the tumour and the sugar metabolism of the tumour 
(with FDG PET). PET/MR has the potential to evaluate additional 
biomarkers that may be key in guiding the choice of interven-
tion; examples might include tumour perfusion, angiogenesis, 
apoptosis, and cell proliferation. The composite picture of these 
biomarkers would allow the design of a personalized treatment 
strategy — extremely critical in the era of more targeted and very 
expensive therapies.
Therapy monitoring
A vital step in the long battle to make cancer a chronic disease 
could come in the form of accurate, non invasive, and safe patient 
monitoring. By not using the radiation of CT, PET/MR can allow 
scans of treated patients to be taken at regular intervals, maximiz-
ing the chance of catching any return of the disease early enough 
to successfully treat it.
Pharmaceutical development
A comprehensive picture of the key biomarkers that are enabled 
by combined PET/MR could be used to develop novel drugs and 
therapies. A whole body scanner could be used in early preclinical 
work, in translating the results into clinical research and eventually 
clinical practice. The combination of PET and MR imaging in a single 
system has brought molecular imaging a giant step closer to reality.
Summary
The future of PET/MR appears to be very bright. There are se-
veral potential clinical applications awaiting their validation. Prelimi-
nary results already demonstrate the value of combined modality 
in oncology (whole body scanning), cardiology (high-risk plaque 
assessment), and neurology. The Philips Ingenuity TF PET/MR 
system is well positioned to provide relevant clinical research data 
by delivering uncompromised performance in both PET (including 
time of flight) and MR (comprehensive 3T imaging portfolio). Once 
again, nuclear medicine is a big part of a new hybrid imaging mo-
dality that is well positioned to change the paradigm of imaging: 
from lesion (disease) detection to characterization.
*This article was provided by Philips Healthcare.
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